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AbstrACt
Introduction Fatigue is a major cause of morbidity, 
limiting quality of life, in patients with antineutrophil 
cytoplasmic antibody-associated vasculitis (AAV). The 
aetiology of fatigue is multifactorial; biological and 
psychosocial mediators, such as sleep deprivation, pain 
and anxiety and depression, are important and may 
be improved by increasing physical activity. Current 
self-management advice is based on expert opinion 
and is poorly adhered to. This study aims to investigate 
the feasibility of increasing physical activity using a 
programme of direct contact and telephone support, to 
provide patient education, encourage behaviour self-
monitoring and the development of an individual change 
plan with defined goals and feedback to treat fatigue 
compared with standard of care to inform the design of a 
large randomised controlled trial to test the efficacy and 
cost effectiveness of this programme.
Methods and analysis Patients with AAV and 
significant levels of fatigue (patient self-report using 
multidimensional fatigue index score questionnaire ≥14) 
will be randomised in a 1:1 ratio to the physical activity 
programme supported by behavioural change techniques 
or standard of care. The intervention programme will 
consist of 8 visits of supervised activity sessions and 
12 telephone support calls over 12 weeks with the 
aim of increasing physical activity to the level advised 
by government guidelines. Assessment visits will be 
performed at baseline, 12, 24 and 52 weeks. The study 
will assess the feasibility of recruitment, retention, the 
acceptability, adherence and safety of the intervention, 
and collect data on various assessment tools to inform the 
design of a large definitive trial. A nested qualitative study 
will explore patient experience of the trial through focus 
groups or interviews.
Ethics and dissemination All required ethical and 
regulatory approvals have been obtained. Findings will be 
disseminated through conference presentations, patient 
networks and academic publications.
trial registration number ISRCTN11929227.
IntroduCtIon 
Fatigue is a common symptom limiting quality 
of life in patients with a wide range of inflam-
matory and other chronic diseases including 
systemic vasculitis.1 Ninety-two per cent of 
patients with antineutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis (AAV) 
consider fatigue as the most important 
symptom affecting their well-being,1 2 and it 
has been causally linked to reduced social 
participation, social withdrawal and unem-
ployment.3 4 Despite the significance of the 
problem, there are currently no recom-
mended therapies specifically for fatigue in 
patients with AAV. Current self-management 
advice provided by the National Institute 
for Health and Care Excellence (https:// 
cks. nice. org. uk/ tirednessfatigue- in- adults#! 
scen ario reco mmen dation: 1) and Arthritis 
Research UK (ARUK) (https://www. arthritis-
researchuk. org/ arthritis- information/ 
daily- life/ fatigue. aspx) is based on expert 
opinion and pragmatic advice without any 
strengths and limitations of this study
 ► Fatigue is a major cause of poor quality of life in pa-
tients with antineutrophil cytoplasmic  antibody-as-
sociated vasculitis (AAV) and has no evidence base 
to direct treatment.
 ► This study will provide the evidence required to de-
sign a large randomised controlled trial to address 
whether physical activity improves fatigue in pa-
tients with AAV.
 ► The study is limited by its size; as a feasibility study, 
it has a small sample size and will not provide evi-
dence of efficacy but will provide estimates to cal-
culate sample size for a larger study
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underpinning evidence base. This is therefore, a major 
area of unmet need and has been identified as a priority 
research area by patients and ARUK.
The aetiology of fatigue is multifactorial5 6 and related 
to a number of interacting central (such as reduced 
motivation and increased perception of effort) and 
peripheral (impaired muscle or cardiovascular function) 
biological and psychosocial mediators including sleep 
deprivation, pain, depression, lack of physical activity 
and reduced cardiovascular fitness, similar to other 
chronic diseases.7–10 Only 47% of patients with AAV 
participate in at least 1 hour of moderate or vigorous 
physical activity per week (unpublished audit of 100 
patients), and patients are reluctant to increase physical 
activity often due to fatigue, or for fear of worsening 
their fatigue.11 Both central and peripheral components 
of fatigue need to be addressed in any successful treat-
ment intervention.
Physical activity interventions improve sleep, quality 
of life, anxiety and depression in patients with chronic 
diseases and have been shown to improve fatigue in the 
short term.12 However, studies with long-term follow-up 
often report no sustained increase in physical activity 
once support is discontinued.13 The addition of cogni-
tive behavioural support (CBS), as commonly imple-
mented in successful chronic disease self-management 
programmes,14 to a physical activity intervention may 
result in improved self-efficacy and a sustained increase 
in physical activity once the formal programme is 
completed.15–18
Our programme, using direct contact and telephone 
support, will provide patient education, encourage 
behaviour self-monitoring and the development of an 
individual change plan with defined goals and feedback 
to increase physical activity. These interventions have 
not been investigated to treat fatigue in patients with 
systemic vasculitis. A pilot study of five patients with AAV 
with fatigue suggested physical activity, supported by 
behavioural intervention, was an acceptable approach for 
patients with AAV and fatigue.19
AIMs And objECtIvEs
The aim of this study is to assess the feasibility and accept-
ability of undertaking a phase III randomised controlled 
trial (RCT) of physical activity with behaviour change 
support including device assisted self-monitoring and 
telephone support with cognitive behavioural strategies 
compared with standard of care in patients with AAV.
The specific objectives of the study are to:
 ► Assess different recruitment methods to the trial for 
example, where and how patients are identified and 
recruited.
 ► Assess recruitment and retention rates in the trial.
 ► Assess the acceptability of the intervention and the 
burden of trial participation on patients.
 ► Assess adherence to the trial intervention.
 ► Assess the safety of the intervention with respect to 
possible injury and deterioration in fatigue levels as a 
result of participating in a physical activity trial.
 ► Assess the effect of trial participation on activity levels 
in patients in the standard care group.
 ► Test procedures for the trial, including delivery of the 
standardised protocolled intervention and administra-
tion of trial questionnaires and other outcome meas-
urement tools, and identify areas that may improve 
the design and implementation of the intervention.
 ► Collect data on the variability of the outcome meas-
ures to inform a power calculation for a definitive 
trial.
 ► Provide an estimate of the cost of implementing the 
intervention.
 ► Collect feedback from patients on their experience of 
participating in the study.
MEthods
overview of study design
This is a single centre, open-label randomised controlled 
feasibility study with a nested qualitative component. 
Feasibility will be determined by assessing recruitment, 
adherence to the intervention and retention rates. Accept-
ability and patient experience will be assessed through 
patient-reported outcome (PRO) questionnaires, and an 
optional nested qualitative study consisting of either focus 
groups or semistructured telephone interviews if insuffi-
cient numbers can be recruited to form focus groups.
Fifty participants will be randomised (via a comput-
er-generated programme) in a 1:1 ratio to the inter-
vention or standard care for this population (figure 1 
study flow). The randomisation will be minimised by age 
(<65 vs ≥65 years). Participants randomised to the inter-
vention arm will complete eight supervised (one per 
week) and 12 telephone coaching sessions over 12 weeks. 
Outcomes will be assessed at baseline, 12, 24 and 52 weeks 
from the first exercise session for those in the interven-
tion group and from randomisation for those in the stan-
dard care group.
sample size
This is a feasibility study, and therefore a formal sample 
size calculation has not been performed. The study is not 
designed or powered to detect a statistically significant 
difference in efficacy between the two treatment arms.
A pragmatic recruitment target of 50 participants has 
been chosen as we expect this number will be feasible 
within a single centre with a population of 250 patients 
and should be sufficient to provide estimates of the feasi-
bility outcomes. A sample size of between 24 and 50 is 
recommended for pilot studies to estimate sample sizes 
for a full trial.20
Patient involvement
The study was designed in consultation with a range of 
patients. A patient research partner (CD) is part of the 
trial management group (TMG) and helped to design the 
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study which was then discussed at patient support group 
meetings and with trustees of Vasculitis UK, the patient 
support charity. Feedback from these meetings was incor-
porated into the study design. Vasculitis UK has helped 
with patient recruitment and will help with dissemination 
of the study results.
Participants and recruitment
Patients will be recruited to the study via the dedicated 
vasculitis service at University Hospitals Birmingham 
NHS Foundation Trust (UHB NHSFT) or via response 
to study adverts placed in the Vasculitis UK newsletter 
or other hospital clinics. Confirmation of eligibility for 
the study will be with the patient’s own clinician. Patients 
are eligible if they are 18 years of age or older, have a 
diagnosis of AAV as classified by the European Medicines 
Agency Algorithm,21 have been in remission for at least 
6 months on the day of consent (defined by Birmingham 
Vasculitis Activity Score Version 3 (BVASv3)22=0 on day 
of consent and prednisolone dose <7.5 mg for 6 months) 
and have significant fatigue levels (multidimensional 
fatigue inventory (MFI)-20 general fatigue score ≥14). 
Exclusion criteria include inability to provide informed 
consent, inability or unwillingness to undertake physical 
activity, comorbidities considered by their own clinician 
to contraindicate an increase in physical activity and an 
inability to understand and complete questionnaires.
standard care group
Patients randomised to the standard of care (control) 
group will receive their standard clinical care and will be 
provided with verbal activity advice as per UK government 
recommendations. Advice on activity will be given after 
randomisation, and patients will be advised to visit the 
government physical activity guidelines website.23
Intervention group
The intervention is a physical activity and behavioural 
change support programme, plus standard care. The 
physical activity intervention will provide support for 12 
weeks; weeks 1–8 will consist of weekly (where possible) 
direct contact in groups of 4–7 patients and additional 
individual telephone health coaching once weekly 
(where possible), then in weeks 9–12, telephone health 
coaching only will be provided. The intervention will be 
staged adapted, and participants will be encouraged to 
increase physical activity within their capabilities. Partic-
ipants will be provided with personal activity self-moni-
toring devices, which are wrist-worn accelerometers 
(Fitbit Model FB405BKL), providing individual feedback 
Figure 1 Consort diagram.
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on daily physical activity. The supervised activity sessions 
will incorporate CBS (eg, goal setting, finding social 
support and understanding the costs/benefits of exer-
cise etc) to promote long-term participation in physical 
activity. The intervention includes education, monitoring 
and assessment of progress and teaches skills to improve 
self-efficacy.
Individual specific, measurable, achievable, realistic and 
timed (SMART) goals24 will be set by the participants with 
guidance from the intervention facilitator and will focus 
on increasing activity levels. The behavioural goal is for 
participants to achieve at least 30 min of moderate inten-
sity activity, 5 days per week, ideally in bouts of 10 min, 
as per UK government recommendations, although any 
increase in physical activity or reduction in sedentary 
time will be viewed positively. The Fitbit activity self-mon-
itor is supported with online web interfaces that facilitate 
effective components of physical activity interventions 
(https://www. fitbit. com/ login).25
A detailed facilitator intervention manual has been 
developed to support the supervised sessions and tele-
phone coaching. In brief, the physical activity interven-
tion is designed to be pragmatic and accessible, taking 
into account exercise preferences and giving choices. 
During the direct contact sessions, participants will be 
asked to complete short bouts (eg, 5×3 min, with 2 min 
rest intervals) of low to moderate intensity aerobic exer-
cise (eg, stepping ergometer, cycle ergometer, treadmill 
walking, rowing ergometer, arm cranking) at 50%–69% 
of predicted maximum heart rate (220—age) or 12–14 on 
the Borg Ratings of Perceived Exertion Scale.26 Intensity 
will be monitored continuously during exercise training 
sessions. As the intervention progresses, participants will 
be encouraged to participate in longer periods of aerobic 
exercise (eg, 5×4 min) or to take shorter rests between 
bouts.
Where appropriate, participants will also be introduced 
to exercises for strength and control, which will typically 
involve two to six different resistance exercises (eg, wall 
press ups, arm curls, leg abduction, wall squats and/or 
regular squats, knee extensions, calf raises, sit-to-stand) 
each session. Body resistance, light weights and Thera-
bands will be used to provide resistance and one to three 
sets of 5 to 20 repetitions will be performed, depending 
on level of disability and strength, as well as stage of 
the programme (exercises will be progressed according 
to individual capabilities and strength gains). Static 
stretching exercises for large skeletal muscle groups will 
be included in the sessions.
Participants will be encouraged to replicate the sessions 
at home supported by the telephone health coaching.
Using activity data collected from the Fitbit device from 
the preceding week, the intervention facilitator will assist 
participants to establish SMART goals.24 Data collected 
will be shared with the therapist, via either the internet 
dashboard or paper diary. Review of daily and weekly 
physical activity will be undertaken to identify bouts of 
moderate/vigorous physical activity and to negotiate 
change plans to increase bouts of moderate/vigorous 
physical activity.
During the telephone discussion, participants will be 
encouraged to use their activity profiles generated from 
their Fitbit device, with data collected and stored using 
the online dashboard or paper diaries, to promote self-de-
termination and self-regulation to achieve personal goals 
and maintain activity. The therapist will review fatigue, 
the impact of physical activity on fatigue and the manage-
ment of fatigue with the participant. The therapist will 
review activity plans and understanding, provide physical 
activity education and help the patient to generate activity 
maintenance plans and set new goals.
study procedures
The study outcomes, measurement methods and assess-
ments are summarised in table 1. Data are collected at 
baseline, and then at 12, 24 and 52 weeks, from the first 
exercise session for those in the intervention group and 
from randomisation for those in the standard care group. 
Data on recruitment, number of activity sessions and tele-
phone coaching sessions completed and drop outs will 
also be recorded.
At the baseline, 12-week and 24-week assessments blood 
pressure, height (baseline only), weight and waist circum-
ference will be measured, disease type, medical and drug 
history (baseline only), use of immunosuppressive therapy 
and assessment of damage associated with AAV, using the 
vasculitis damage index27 (baseline only) will be taken. 
Laboratory investigations, including full blood count and 
kidney function are measured at baseline. At each assess-
ment visit, disease activity will be assessed using the BVASv3. 
Clinical outcomes and safety of the intervention, including 
muscle or bone injury, disease relapse and cardiovascular 
adverse clinical events will be collected at 12 and 24 weeks 
as self-reported by the participant. All serious adverse events 
will also be recorded. Participants will complete a suite of 
validated health-related quality of life and fatigue ques-
tionnaires, which include short form-36 (SF-36),28 ANCA 
Vasculitis questionnaire (AAV-PRO), EQ-5D,29 MFI-20,30 
Pittsburgh Sleep Index,31 Bristol Rheumatoid Arthritis 
Fatigue-Multidimensional questionnaire,32 Hospital Anxiety 
and Depression score,33 Brief Coping Orientation to Prob-
lems Experienced (Brief COPE) questionnaire34 and the 
International Physical Activity Questionnaire long version at 
baseline and at 12, 24 and 52 weeks (at 52 weeks, the partic-
ipants will be contacted by post and asked to complete the 
same questionnaires as completed at previous assessments 
and to return these by post or at next clinic visit). All partic-
ipants will be asked to wear an accelerometer (GENEActive 
GATV01, Activinsights, Kimbolton, UK) for 7 days at base-
line and at 12 and 24 weeks to provide an objective measure 
of their activity.
In order to undertake an analysis of all the direct 
resources and costs required to deliver the intervention, 
a detailed collection of health economic data will be 
embedded within the trial.
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study outcomes and data analysis
The primary outcome of this feasibility trial is to deter-
mine if a full RCT comparing physical activity with 
behaviour change support versus standard care in patients 
with AAV is feasible. This decision will be made using a 
composite assessment of both quantitative and qualita-
tive data based on a traffic light system using predefined 
stop-go criteria. The three criteria contributing to the 
traffic light system include1 recruitment rates, defined 
as the proportion of eligible patients recruited into the 
study2; successful adherence to the intervention, defined 
as attendance at a minimum of 4 of the 8 visits for the 
face to face support, and acceptance of a minimum of 3 
of the 4 telephone support calls in weeks 9–12 and3 study 
drop-out, defined as complete withdrawal from the study, 
with no further data collected from the participant. The 
traffic light system comprises (1) green light: recruitment 
rate >50%; adherence rate >75% and drop-out rate <15% 
excluding those patients who drop-out or are unable 
to achieve adherence due to disease activity. If all three 
criteria are met, we will proceed to a full trial with the 
protocol unchanged (unless there is a clear message from 
the qualitative work that would improve the protocol). (2) 
Amber light: recruitment rate 30%–50%, adherence rate 
50%–75% or drop-out rate 15%–30% excluding those 
patients who drop-out or are unable to achieve adher-
ence due to disease activity. If one or more of our amber 
light criteria are met, we will adapt the protocol in light 
of the result of the feedback from the qualitative work 
and our experience to improve whichever criteria are not 
at the ‘green-light’ level before proceeding to full trial if 
possible. We will assess whether adaption of the protocol 
will require a further feasibility study or pilot study before 
progressing. (3) Red light: recruitment rate <30%, adher-
ence rate <50% or drop-out rate >30% excluding those 
patients who drop-out or are unable to achieve adherence 
for disease activity. If one or more of these criteria are met 
we would consider the current protocol not feasible and 
not progress to a full RCT.
The primary analysis to assess the stop-go criteria will 
be undertaken once all participants have completed 
the 24-week assessment, and corresponding outcome 
data has been entered onto the study database and vali-
dated as being ready for analysis. Feasibility outcomes 
including the three components of the stop-go criteria 
will be analysed by pooling the two randomised groups 
and presenting overall estimates with 95% CI. Reasons 
for non-entry into the trial will be assessed, particularly 
in relation to the patient eligibility criteria and reasons 
for patient refusal. Data on patients who stop the inter-
vention and/or who do not complete the trial (such as 
withdrawals and those lost to follow-up) will be collected 
throughout the trial to allow assessment of patient adher-
ence and retention rates. Reasons for non-adherence and 
non-completion will be analysed descriptively.
All clinical and patient-reported outcomes will 
primarily take the form of simple descriptive statistics 
(eg, proportions and percentages, means and SD) and 
where appropriate, point estimates of effects sizes (eg, 
mean differences and relative risks) and associated 95% 
CI. Data return rates at each time point will be assessed 
along with data completeness of the various outcomes 
measures. This will inform the use of appropriate ques-
tionnaires for the primary outcome in a future study. The 
Table 1 Visit overview
Visit Prebaseline Baseline
Baseline 
(+4 weeks) Weeks 1–8 Weeks 9–12 Week 12* Week 24*
†Week 
52*
Identification of eligible patients x
Eligibility check x x
Valid informed consent x
Relevant medical history taken x
Randomisation (without patient 
present)
x
Activity advice telephone call 
(control arm only)‡
x
Exercise visits (intervention arm 
only)
x
Weekly telephone coaching 
contacts (intervention arm only)
x x
Follow-up clinic visits*§ x x
Final assessment (postal 
questionnaires)*§
x
Quality of life questionnaires x x x x
Focus groups or interviews 
(postintervention)
x x x
*The timing of the follow-up visits for intervention group are taken from intervention start date, not randomisation date; for the control group, the timing is taken 
from randomisation date.
†52 weeks follow-up assessment can be completed—2 weeks before due date and up to 8 weeks after the due date.
‡Control group have one telephone call in week 1 (postrandomisation) to receive standard activity advice only.
§12-week and 24-week follow-up assessments can be completed up to—2 weeks before due date and up to 3 weeks after the due date.
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data will be analysed using the intention to treat prin-
ciple, where patients are analysed in the treatment group 
to which they were randomised regardless of adherence 
to intervention or compliance with the protocol.
Detailed data collection of the resources required to 
deliver the intervention will allow a cost analysis to be 
undertaken to calculate the cost of implementing the 
intervention in a full RCT. The mean cost of the inter-
vention per patient will be estimated both as per usage 
in the study and also the full cost assuming full compli-
ance. Data collected directly from the trial will determine 
the resources required for delivering the supervised 
exercise and telephone health coaching. Resources will 
include staff costs, any equipment/consumables needed, 
printed material, telephone call costs, staff training costs 
and infrastructure (eg, room space). Information will be 
collected on number of patient contacts, length of time 
for face to face and telephone contacts and group size for 
the supervised exercise sessions. Standard unit costs for 
healthcare will be applied, with local costs sought from 
participating healthcare providers. Sensitivity analysis will 
estimate costs with changes to costing assumptions, for 
example, staff grade, group size.
nested qualitative study
Focus groups of 4–6 participants will be carried out to 
discuss their experience of the trial. Two groups will consist 
of people who participated in the trial and participated in 
the intervention, one group of people who participated 
and received standard of care and the final group will be 
made up of people who did not wish to participate in the 
trial. Individuals who did not wish to participate in the 
trial will be contacted and invited to participate in a focus 
group to better understand the reasons for non-participa-
tion. If we cannot form one or more of the focus groups 
described, then patients will be invited to participate in 
1:1 semistructured telephone interviews. The qualitative 
phase will be conducted by a researcher not involved with 
the rest of the study and will collect data on the experi-
ences of the study and the intervention, in more detail, 
and to gather suggestions for improvements to the design 
of a future RCT.
Focus groups and interviews will be recorded and 
transcribed verbatim. QSR NVivo 8 will be used for 
data management and data analysed using a framework 
approach,35 facilitated by the use of to identify freely 
emerging themes and categories. Those who did not 
participate in the trial will be invited to complete the same 
questionnaires as collected during the trial. These will be 
analysed as above using simple descriptive statistics.
trial management and monitoring
The trial will be coordinated by the TMG (principal 
investigator, coinvestigators, trial coordinator, physical 
activity trainer and statistical advisors) in conjunction 
with the NIHR/WT CRF. A Trial Steering Committee 
(TSC) consisting of the principal investigator as well as 
three independent consultants, a statistician and patient 
advocate not involved in the study will provide the overall 
supervision of the trial. The TSC will oversee trial prog-
ress, protocol compliance, patient safety and review of 
updated information. As this is a feasibility study with 
short follow-up, no Data Monitoring Committee will be 
formed, as agreed with the sponsor. The integrity of data 
entry will be ensured using a trial-specific Data Input 
Quality Control standard operating procedure (Trial 
Master File, University of Birmingham). The trial data-
base will contain date of birth and sex. Data analyses will 
be undertaken on pseudoanonymised datasets. All source 
data and original participant identities will be kept in a 
locked office in the trial site file only at UHB NHSFT or 
at Birmingham Clinical Trials Unit.
Ethics
All patients will be provided with verbal and written study 
information. The study will be undertaken at a single 
site, and local governance approval has been granted by 
UHB NHSFT. Steps have been taken to ensure patient 
welfare when designing this study. The study complies 
with the International Conference for Harmonisation 
of Good Clinical Practice guidelines and the Research 
Governance Framework for Health and Social Care. Any 
protocol amendments will be submitted to the sponsor 
and relevant regulatory bodies for approval prior to 
implementation, and trial participants will be informed 
of any protocol modifications.
dissemination policy
It is anticipated that the findings of this study will be 
published in peer-reviewed journals, presented at national 
conferences, and that the results will be disseminated to 
all study participants who wish to be informed. It is antic-
ipated that the results of this study will inform the design 
of a large RCT investigating the efficacy of increasing 
physical activity to treat fatigue in this population.
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